Guodong Hu

Dr. Guodong Hu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Research
Verified
Journal Article
Open access
PZPing Zhu
Ping Zhu
ZWZhaoji Wu
Zhaoji Wu
ZYZhilu Yang
Zhilu Yang
TTTingting Tang
Tingting Tang
YLYunhui Liao
Yunhui Liao
YCYinghua Chen
Yinghua Chen
Hyperproliferative keratinocytes and subcutaneous inflammation contribute to the characteristic symptoms of psoriasis, including erythema, scales, or scaly plaques on the skin. These symptoms significantly affect patients’ quality of life and cause severe physical and psychological distress. However, current treatment strategies have limited therapeutic effect and may lead to adverse side effects. In this study, we present the novel organic photosensitizer TBTDC [5-(((5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)methylene)amino)-3-methylthiophene-2,4-dicarbonitrile] nanoparticles (NPs) with aggregation-induced emission (AIE) characteristics to mediate photodynamic therapy (TBTDC NP-PDT) for psoriasis treatment. We demonstrate that TBTDC NPs effectively generate reactive oxygen species upon light irradiation and lead to significant apoptosis of psoriatic keratinocytes. Furthermore, TBTDC NPs exhibit high cellular uptake in diseased keratinocytes and induce endoplasmic reticulum stress (ERS)-mediated autophagy, which can also enhance apoptosis. Importantly, TBTDC NPs show no cytotoxicity toward keratinocytes. These unique properties of TBTDC NPs enable remarkable therapeutic effects against psoriasis-like skin lesions and related inflammation in vivo. Overall, our AIE-active TBTDC NP-PDT represents a promising strategy for treating psoriasis in clinical settings.

4 November 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
CNChunmei Nong
Chunmei Nong
ZWZhenzhen Wu
Zhenzhen Wu
CYChan Yang
Chan Yang
WXWei Xu
Wei Xu
LLLinyi Luo
Linyi Luo
GHGuodong Hu
Guodong Hu
Introduction: SARS-CoV-2 infection drove senescent cells and the senescence-associated phenotypes were reported playing roles in disease progression, which contributes to severe COVID-19 and related sequelae. Cdc42 is involved in the regulation of cellular senescence. This study, aimed to investigate the mechanism of the SARS-CoV-2 spike protein regulating cellular senescence through Cdc42.Methods: K18-hACE2 mice were infected with SARS-CoV-2 Omicron BA.4 or stimulated with spike protein through the airway, the senescent cells and Cdc42 expression in lung tissue were detected. Overexpression of spike protein or exogenous incubation of spike protein was used to simulate the induction of cellular senescence by spike protein. Mechanistic insights into the role of Cdc42 were mainly explored using Western Blot and qRT-PCR.Results: Spike protein, SARS-CoV-2 infection related, accelerates cell aging by upregulating Cdc42 expression, which furtherly activated the Wnt/β-catenin signaling pathway. Conversely, treatment with ML141 in animal models, a Cdc42 inhibitor, reduced cellular senescence and ameliorated lung injury and inflammation. These results suggest that the upregulation of Cdc42 by the SARS-CoV-2 spike protein induces cellular senescence and enhances β-catenin nuclear translocation.Discussion: This study provides insights into the mechanisms underlying cellular senescence induced by the SARS-CoV-2 spike protein, offering potential strategies to mitigate the inflammatory response and complications associated with COVID-19 in both the acute and long-term phases.

24 March 2025 in BMC Genomics
Verified
Journal Article
Open access
PDF file
SPShisheng Peng
Shisheng Peng
JFJinlong Fang
Jinlong Fang
WMWeiliang Mo
Weiliang Mo
GHGuodong Hu
Guodong Hu
SWSenquan Wu
Senquan Wu
Previous studies have reported several genetic loci associated with lung function. However, the mediating mechanism between these genetic loci and lung function phenotype is rarely explored. In this research, we used a cross-tissue multi-omics post-GWAS analysis to explain the associations between DNA methylation, gene expression, and lung function. We conducted integration analyses of lung function traits using genome-wide association study (GWAS) summary data alongside expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) derived from whole blood, utilizing multi-omics SMR and Bayesian colocalization analysis. Considering the genetic differences of tissues, we replicated the shared causal signals of eQTLs and lung function in 48 diverse tissues and the shared causal signals of mQTLs and lung function in 8 diverse tissues. Multi-trait colocalization analyses were utilized to identify the causal signals between gene expression in blood, blood cell traits, and lung function, as well as between cross-tissue gene expression in diverse tissues and lung function. Eight genes from blood tissue were prioritized as FEV1 causal genes using multi-omics SMR analysis and COLOC colocalization analysis: EML3, UBXN2A, ROM1, ZBTB38, RASGRP3, FAIM, PABPC4, and SNIP1. Equally, five genes (CD46, EML3, UBXN2A, ZBTB38, and LMCD1) were prioritized as FVC causal genes and one gene (LMCD1) was prioritized as FEV1/FVC causal genes. The causal signals between 8 genes (EML3, ROM1, UBXN2A, ZBTB38, RASGRP3, FAIM, PABPC4, and CD46) and lung function were successfully replicated in diverse tissues. More importantly, MOLCO colocalization analysis showed that 3 genes (CD46, LMCD1, and ZBTB38) expression in blood, blood cell traits, and lung function traits shared the same causal signals. Finally, through cross-tissue colocalization analysis of multiple traits, we found that the heart–lung axis EML3 expressions and lung function mediate the same causal signal. This study identified potential cross-tissue molecular targets associated with lung function traits from DNA methylation and gene expression of diverse tissues and explored the probable regulation mechanism of these molecular targets. This provides multi-omics and cross-tissue evidence for the molecular regulation mechanism of lung function and may provide new insight into the influence of crosstalk between organs and tissues on lung function.

17 June 2025 in Phytomedicine
Verified
Journal Article
Closed access
CYChan Yang
Chan Yang
KLKunyu Lu
Kunyu Lu
JWJinshen Wang
Jinshen Wang
HSHao Su
Hao Su
LCLuping Cheng
Luping Cheng
Shuwen LiuShuwen Liu
Shuwen Liu

30 March 2026 in Heart & Lung
Verified
Journal Article
Closed access
KCKai Cheng
Kai Cheng
SFSodiq Fakorede
Sodiq Fakorede
GHGuodong Hu
Guodong Hu
RWRongjun Wan
Rongjun Wan
NFNianxin Fang
Nianxin Fang
QZQuan Zhang
Quan Zhang

1 January 2025 in MEDS Clinical Medicine
Verified
Journal Article
Open access
PDF file
YCYanrong Chen
Yanrong Chen
YCYinghua Chen
Yinghua Chen
SYShuang Yang
Shuang Yang
HJHongli Jiao
Hongli Jiao
ZCZhao Chen
Zhao Chen
GHGuodong Hu
Guodong Hu
Although sildenafil is approved for erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), its association with pulmonary side effect has not been previously reported. This case underscores the potential risk of pulmonary vascular dilation, tortuosity, and airway mucosal bleeding associated with chronic sildenafil administration. This case report describes a 44-year-old male presenting with a 1-year history of cough and productive sputum, which worsened over the past 3 days. The patient reported no smoking history but had been using sildenafil for 7 years to manage ED. Electronic bronchoscopy identified diffuse punctate hemorrhagic spots in the multilevel-bronchial mucosa. Three-dimensional contrast-enhanced CT angiography of the thoracic aorta revealed dilated and tortuous pulmonary bronchial arteries, along with focal dilation of the pulmonary arterioles and venules. After ruling out alternative diagnoses, chronic sildenafil administration was identified as the culprit cause of pulmonary vascular dilation and mucosal bleeding in this patient. At the 6-month follow-up after sildenafil discontinuation, the patient reported complete resolution of cough. Repeat bronchoscopy: No residual hemorrhagic spots in the tracheobronchial mucosa. Clinicians should maintain heightened vigilance for pulmonary vascular dilation and subsequent hemorrhage risk associated with chronic sildenafil use. The diagnosis of pulmonary vascular abnormalities and airway bleeding necessitates explicit consideration of sildenafil exposure in the differential diagnosis.